IRIS
PICCIOTTO, ANTONINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.490
AS - Asia 1.002
NA - Nord America 536
SA - Sud America 83
AF - Africa 20
OC - Oceania 3
Totale 13.134
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 11.333
US - Stati Uniti d'America 495
SG - Singapore 442
CN - Cina 267
VN - Vietnam 174
FR - Francia 83
BR - Brasile 51
HK - Hong Kong 33
BD - Bangladesh 24
FI - Finlandia 23
CA - Canada 20
AR - Argentina 17
JP - Giappone 17
MX - Messico 14
DE - Germania 12
IQ - Iraq 9
IN - India 8
CH - Svizzera 7
GB - Regno Unito 7
NL - Olanda 6
ZA - Sudafrica 6
KR - Corea 5
MA - Marocco 5
VE - Venezuela 4
AU - Australia 3
EC - Ecuador 3
IE - Irlanda 3
JO - Giordania 3
KE - Kenya 3
PE - Perù 3
PH - Filippine 3
BY - Bielorussia 2
CL - Cile 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
ID - Indonesia 2
LT - Lituania 2
MD - Moldavia 2
PS - Palestinian Territory 2
PT - Portogallo 2
RU - Federazione Russa 2
SA - Arabia Saudita 2
TR - Turchia 2
UA - Ucraina 2
AZ - Azerbaigian 1
BH - Bahrain 1
BO - Bolivia 1
CO - Colombia 1
CR - Costa Rica 1
EG - Egitto 1
ES - Italia 1
ET - Etiopia 1
HN - Honduras 1
HR - Croazia 1
HT - Haiti 1
JM - Giamaica 1
KZ - Kazakistan 1
LB - Libano 1
PK - Pakistan 1
RO - Romania 1
RW - Ruanda 1
SC - Seychelles 1
SI - Slovenia 1
TH - Thailandia 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 13.134
Salva come PNG Salva come JPEG
Città #
Genova 7.457
Genoa 2.233
Rapallo 954
Vado Ligure 647
Singapore 198
San Jose 175
Lauterbourg 80
Ashburn 54
Ho Chi Minh City 51
New York 42
Beijing 38
Hanoi 34
Hong Kong 31
Helsinki 22
Council Bluffs 21
Santa Clara 16
Los Angeles 15
Tokyo 15
Bordighera 11
Frankfurt am Main 10
Mexico City 9
Da Nang 8
Orem 7
Tianjin 7
Zurich 7
Amsterdam 6
Haiphong 6
Montreal 6
Dallas 5
Atlanta 4
Biên Hòa 4
Milan 4
San Francisco 4
São Paulo 4
Toronto 4
Bình Dương 3
Charlotte 3
Des Moines 3
Dublin 3
Guangzhou 3
Hải Dương 3
Mosul 3
Phoenix 3
Rome 3
Sorocaba 3
Thái Nguyên 3
Ahmedabad 2
Amman 2
Baton Rouge 2
Boardman 2
Buffalo 2
Bắc Giang 2
Bắc Ninh 2
Cabo Frio 2
Cape Town 2
Chicago 2
Houston 2
Johannesburg 2
London 2
Lấp Vò 2
Minsk 2
Nairobi 2
Naples 2
Quito 2
Quận Ba 2
Rio de Janeiro 2
Shenzhen 2
Sydney 2
Tampa 2
Tân Tiến 2
Ubatuba 2
Zhengzhou 2
Actopan 1
Addis Ababa 1
Agadir 1
Al Kazimiyah 1
Al Maḩallah al Kubrá 1
Alexandria 1
Almaty 1
Alpharetta 1
Altopascio 1
Amarillo 1
Andover 1
Ankara 1
Baghdad 1
Bang Lamung 1
Barbacena 1
Basingstoke 1
Batna City 1
Bengaluru 1
Berazategui 1
Bloomfield 1
Boston 1
Brasília 1
Bridgeport 1
Cachoeira Paulista 1
Cachoeirinha 1
Cagayan de Oro 1
Caicó 1
Calamba 1
Totale 12.302
Salva come PNG Salva come JPEG
Nome #
Non-antigen-specific CD8(+) T suppressor lymphocytes in diseases characterized by chronic immune responses and inflammation. 269
A new assay for hepatitis C virus (HCV) core antigen detection: an alternative to nucleic acid technologies in positive or indeterminate anti-HCV subjects? 220
Hepatitis G virus infection in haemodialysis and in peritoneal dialysis patients. 218
Autoimmune intrahepatic cholangiopathy associated with antiphospholipid antibody syndrome 210
Epidemiological and clinical features of hepatitis delta in HBsAg-positive patients by HIV status. 202
'Emergency exit' of bone-marrow-resident CD34+ DNAM-1 bright CXCR4+-committed lymphoid precursors during chronic infection and inflammation 200
Circadian monitoring of gastric juice mutagenicity. 199
Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy: an early predictor marker of response? 193
Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study 191
S-adenosil-L-methionine is able to reverse the immunosuppressive effects of chenodeoxycholic acid in vitro. 186
Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy 181
Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis 181
Anti-hepatitis C virus antibodies and hepatitis C virus viraemia in haemodialysis patients 180
Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment. 179
Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy 178
Biopsychosocial predictors of interferon-related depression in patients with Hepatitis C 176
Circadian reduction of chromium in the gastric environment. 175
A case of drug rash with eosinophilia and systemic symptoms (DRESS) induced by telaprevir associated with HHV-6 active infection 171
Peripheral blood serum markers for apoptosis and liver fibrosis: Are they trustworthy indicators of liver realness? 170
T cells from patients with chronic liver diseases: abnormalities in PHA-induced expression of HLA class II antigens and in autologous mixed-lymphocyte reactions. 169
Liver transplantation in type III von Willebrand disease 168
Mutagenicity of cimetidine in nitrite-enriched human gastric juice. 166
Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients 164
Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. 163
Comparison between laparoscopy, ultrasonography, and computed tomography in widespread and localized liver diseases. 159
Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis 159
Successful antiviral therapy determines a significant decrease in squamous cell carcinoma antigen-associated (SCCA) variants' serum levels in anti-HCV positive cirrhotic patients. 158
Interferon retreatment in chronic hepatitis C: wich patients to choose, and what schedule to use 156
Antiviral activity of amantadine in elderly patients with chronic hepatitis C 156
Prevalence and Undertreatment of Prothrombotic Risk in Advanced Forms of Liver Disease 154
Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C. 153
A single-blind pilot study comparing standard and half bedtime doses of ranitidine in the short-term healing of duodenal ulcer. 153
Clearance kinetics of hepatitis C virus under different antiviral therapies. 153
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. 152
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 152
Is hepatic ultrasonography a valid alternative tool to liver biopsy? Report on 507 cases studied with both techniques. 149
Clinical and virological survey of patients with hepatitis B surface antigen in an Italian region: clinical considerations and disease burden 148
Single bedtime dose of famotidine: assessment of its antisecretory action by 24-hour intragastric pH monitoring. 148
Increased beta2-microglobulin-free HLA class I heavy chain serum levels in the course of immune responses to viral antigens and to mismatched HLA antigens. 147
Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy. 146
Inherent transcriptional signatures of NK cells are associated with response to IFNΑ+rivabirin therapy in patients with Hepatitis C Virus 146
Continuous lamivudine treatment in an OLT patient despite the appearance of HBV resistant strain: longitudinal analysis. 144
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 144
Are clinical patterns of dyspepsia a valid guideline for appropriate use of endoscopy? A report on 2253 dyspeptic patients. 143
A significant proportion of patients with chronic hepatitis B who are candidates for antiviral treatment are untreated: a region-wide survey in Italy 142
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 141
Monotherapy with Pegylated Interferon Alpha-2a in Hemodialyzed Patients with Chronic Hepatitis C 140
Virological and biochemical responses to interferon-a in chronic hepatitis C 138
Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies 138
HOMA, BMI, and serum leptin levels variations during antiviral treatment suggest virus-related insulin resistance in noncirrhotic, nonobese, and nondiabetic chronic hepatitis C genotype 1 patients 138
Long-term interferon alfa-2b retreatment of relapsing patients with chronic hepatitis C. 136
Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients. 135
Predictive factors for response to Peginterferon-Alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more 135
Medical report type in liver transplantation as a quality system document: new prospects for computerization. 133
Porphyrin Elevation in a Patient on Treatment With Simeprevir: Could It Be a Possible Explanation for Simeprevir-Associated Photosensitivity? 133
Hepatic Elastometry and Glissonian Line in the Assessment of Liver Fibrosis 133
Effects of Interferon therapy on monoethylglycinexylidide formation in patients with chronic active hepatitis C 132
Elevations in ALT levels late the course of antiviral therapy in HCV-RNA negative patients are associated with virological relapse 130
TT virus infection in haemodialysis patients 128
Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin. 127
Chronic hepatitis C. New therapeutic strategies. 127
Prospective evaluation of primary infection due to HCV, HGV or TTV in children with newly diagnosed neoplasia. 126
The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real-life experience 124
Soluble tumor necrosis factor-related ligand (sTRAIL) levels and kinetics during antiviral treatment in chronic hepatitis C 123
Serum lamivudine levels in the presence of a lamivudine-resistant HBV mutant 122
Amantadine: a different approach. 122
Macroamylasemia: a possible cause of unexplained hyperamylasemia in rheumatoid arthritis. 121
Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. 120
Hepatitis C in the elderly: A multicentre cross-sectional study by the Italian Association for the Study of the Liver 119
Use of Victoria blue in the detection of intrahepatocyte HBs Ag: comparison with other methods. 118
Diabetic hepatosclerosis presenting with severe cholestasis 117
First experimental proof of Proton Boron Capture Therapy (PBCT) to enhance protontherapy effectiveness 117
Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension. 115
Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C. 114
EVALUATION OF HEPATIC FIBROSIS WITH TRANSIENT ELASTOGRAPHY (FIBROSCAN) AND APRI SCORE IN PATIENTS WITH SYSTEMIC SCLEROSIS AND ITS CORRELATION WITH PULMONARY, CARDIAC, RENAL AND ESOPHAGEAL INVOLVEMENT 112
Biochemical scores could reflect histological activity in chronic hepatitis C 111
Initial high dose of lamivudine delays the appearance of viral resistance in chronic hepatitis B patients 102
Evaluation of a new hepatitis C virus sequecing assay as a routine method for genotyping 102
Serum intercellular adhesion molecule-1 and long-term response to IFN-alpha2b therapy in chronic hepatitis C 101
Therapeutic management of chronic hepatitis B in clinical Practice: a region-wide survey. 100
Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation 100
Hepatitis C recurrence: Split liver versus whole size graft. 98
Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls. 97
Effect of a common missense variant in LIPA gene on fatty liver disease and lipid phenotype: New perspectives from a single-center observational study 97
Predictability and survival in liver replantransplantation: Monocentric experience 96
Probability of non-response during interferon therapy in patients with chronic hepatitis C 93
Pityriasis rosea in a hepatitis b-positive patient treated with pegylated interferon α2a: Report of a case and review of the literature 90
Postprandial serum bile acids after ursodeoxycholic acid. A possible test of intestinal absorption? 89
Metabolic activation of food hepatocarcinogens in hepatitis B virus-infected humans and animals. 87
Detection of anti-HCV IgM antibodies in patients with chronic hepatitis C treated with interferon 85
Iodized oil pleural effusion in a patient previously treated with transarterial chemoembolization for hepatocellular carcinoma 84
Soluble beta2-mu-associated and beta2-mu-free HLA class I heavy chain serum levels in interferon-alpha nonresponder chronic hepatitis C patients. Markers of immune activation, and response to antiviral retreatment. 76
Role of dietary intervention in patients with metabolic syndrome and {NAFLD}-{NASH} 69
Individualized treatment of genotype 1 Naïve patients: An Italian multicenter field practice experience 64
Totale 13.226
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.931
article - articoli 39.441
book - libri 0
conference - conferenze 490
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 79.862
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202161 0 0 0 0 0 0 0 0 0 0 0 61
2021/20221.168 36 63 73 145 47 81 69 262 92 104 47 149
2022/20231.134 115 105 11 107 175 192 3 95 205 11 105 10
2023/2024463 19 80 8 59 32 63 25 30 30 9 40 68
2024/20251.574 52 106 35 108 248 154 138 279 51 59 148 196
2025/20262.511 374 53 122 191 347 268 417 121 178 243 162 35
Totale 13.226